{"analyses":[{"ciLowerLimit":"0.670","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.289","groupDescription":"Hazard ratio was based on the Cox Proportional hazards model stratified by UISS High-Risk Group.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.661","paramType":"Hazard Ratio (HR)","paramValue":"0.929","statisticalMethod":"Log-rank test"}],"classes":[{"categories":[{"measurements":[{"comment":"Data was not estimable due to small number of participants with an event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data was not estimable due to small number of participants with an event.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"306"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Every 12 weeks until the time for final analysis (up to data cut-off date: 30 April 2017; maximum exposure:14.9 months)","title":"Overall Survival (OS)- (Stratified by UISS High Risk Group-Intent to Treat Population)","type":"SECONDARY","unitOfMeasure":"Year"}